MA
FOLD

MCF Advisors’s Amicus Therapeutics FOLD Stock Holding History

MCF Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-251
Closed -$3K – 454
2019
Q1 		$3K Buy
251
+10
+4% +$122 ﹤0.01% 405
2018
Q4 		$2K Sell
241
-76
-24% -$835 ﹤0.01% 446
2018
Q3 		$4K Buy
+317
New +$4.43K ﹤0.01% 404

Other funds holding FOLD

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

MCF Advisors's FOLD Position: Q2 2019 in Review

MCF Advisors sold out of Amicus Therapeutics (FOLD) in Q2 2019, closing a stake of 251 shares — an estimated $3K sold.

MCF Advisors first reported a position in FOLD in Q3 2018 and held it in 3 quarters. The position peaked at $4K in Q3 2018. 206 funds tracked by Wall St. Rank hold FOLD as of Q2 2019.

  • MCF Advisors reported no remaining Amicus Therapeutics position as of Q2 2019 after selling out during the quarter.
  • MCF Advisors sold 251 Amicus Therapeutics shares in Q2 2019, an estimated $3K.
  • MCF Advisors first reported a position in Amicus Therapeutics in Q3 2018 and held it in 3 quarters.
  • MCF Advisors's Amicus Therapeutics position peaked at $4K in Q3 2018.
  • 206 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2019.

Based on MCF Advisors's 13F filing for Q2 2019, filed 6 Aug 2019.